WHO ICTRP trial
Clinical effects of everolimus in the subjects with autism spectrum disprders…
JPRN-jRCT1090220258 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT1090220258 |
|---|---|
| Public title | Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis. |
| Scientific title | Clinical effects of everolimus in the ubjects with tuberous sclerosis. - Clinical effects of everolimus in the subjects with ASD |
| Primary sponsor | Kunio Yui |
| Secondary sponsors | Shinobu Fukumura ant 19 pediatricians. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Countries | Japan |
| Conditions | there are a few individuals with TSC with SEGA who exhibite ASD symptoms. |
| Interventions | Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature:POWDER Route of administration / Site of application:ORAL Dose per administration:3.5mg 3.5mg/M2 mg/M2 Dosing frequency / Frequency of use:QD once a… |
| Registration date | Feb 8, 2016 |
| Target size | 20 |
| Secondary IDs | JMA-IIA00258 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: